Lucia L Corral

List of Publications by Year
in descending order

100 papers	3,535 citations	147726 31 h-index	149623 56 g-index
102 all docs	102 docs citations	102 times ranked	5057 citing authors

#	Article	IF	Citations
1	Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. Transplantation and Cellular Therapy, 2022, 28, 258.e1-258.e8.	0.6	4
2	Safety and Efficacy Comparison of Two Anakinra Dose Regimens for Refractory CRS or Neurotoxicity after CAR T-Cell Therapy. Transplantation and Cellular Therapy, 2022, 28, S185-S186.	0.6	0
3	Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Advances, 2022, 6, 3606-3610.	2.5	35
4	Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 2021, 56, 917-927.	1.3	8
5	Defibrotide in hematopoietic stem cell transplantation: A multicenter survey study of the Spanish Hematopoietic Stem Cell Transplantation Group (GETH). European Journal of Haematology, 2021, 106, 842-850.	1.1	2
6	Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. Bone Marrow Transplantation, 2021, 56, 1919-1928.	1.3	13
7	Treatment of steroidâ€refractory chronic graftâ€versusâ€host disease with imatinib: Realâ€life experience of the Spanish group of hematopoietic transplantation (GETH). Clinical Transplantation, 2021, 35, e14255.	0.8	5
8	Realâ€world evidence of tisagenlecleucel for the treatment of relapsed or refractory large Bâ€cell lymphoma. Cancer Medicine, 2021, 10, 3214-3223.	1.3	73
9	COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia, 2021, 35, 2885-2894.	3.3	153
10	Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroidâ€resistant acute and chronic graftâ€vsâ€host disease after allogenic hematopoietic stem cell transplant. Journal of Clinical Apheresis, 2021, 36, 697-710.	0.7	8
11	Longâ€term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for highâ€risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Partyâ€EBMT. British Journal of Haematology, 2021, , .	1.2	2
12	Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood, 2021, 138, 2837-2837.	0.6	8
13	Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study. Blood, 2021, 138, 3850-3850.	0.6	0
14	Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy. Blood, 2021, 138, 2816-2816.	0.6	11
15	Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT. Blood, 2021, 138, 3954-3954.	0.6	0
16	Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain. Blood, 2021, 138, 1742-1742.	0.6	1
17	Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT. Bone Marrow Transplantation, 2020, 55, 461-463.	1.3	3
18	Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation. Bone Marrow Transplantation, 2020, 55, 419-430.	1.3	6

#	Article	IF	Citations
19	Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transplantation, 2020, 55, 641-648.	1.3	58
20	Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma â€“ a LWPâ€EBMT study. British Journal of Haematology, 2020, 188, 745-756.	1.2	20
21	Measures to Maintain a SARS-CoV-2 Negative Inpatient Hematological Unit in the Midst of the COVID-19 Pandemic. Frontiers in Medicine, 2020, 7, 462.	1.2	1
22	CT-177: Predictive Value of Early Measurement of ST2 and REG3Î± in the Outcome of Haploidentical Stem-Cell Transplantation with Post-Transplant Cyclophosphamide. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S215-S216.	0.2	0
23	IBCL-176: Single-Centre Experience with Stem-Cell Transplantation in Patients with Transformed Lymphoma: A Potential Curative Option. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S278-S279.	0.2	0
24	Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. Haematologica, 2019, 104, 929-936.	1.7	23
25	CAR T-CELLS ARE ARRIVING. IS ALLOGENEIC TRANSPLANT AN OBSOLETE APPROACH FOR DE NOVO/TRANSFORMED DLBCL IN THE CAR T-CELLS ERA? LONG-TERM FOLLOW-UP OF A SINGLE CENTRE UNIT. Hematological Oncology, 2019, 37, 508-509.	0.8	1
26	Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms. Clinical Cancer Research, 2019, 25, 4616-4623.	3.2	13
27	Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, 1703-1712.	2.0	13
28	Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 1133-1137.	1.3	0
29	Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 757-761.	1.3	27
30	Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime. Blood, 2019, 134, 3325-3325.	0.6	0
31	Tâ€cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3â€ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology, 2018, 93, 736-744.	2.0	21
32	CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2018, 24, 964-972.	2.0	19
33	Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting. Medical Oncology, 2018, 35, 79.	1.2	15
34	Incidence, Risk Factors and Treatment Response in Patients with Chronic Graft versus-Host Disease after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S304.	0.2	0
35	Busulfanâ€based myeloablative conditioning regimens for haploidentical transplantation in highâ€risk acute leukemias and myelodysplastic syndromes. European Journal of Haematology, 2018, 101, 332-339.	1.1	11
36	Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study. Biology of Blood and Marrow Transplantation, 2018, 24, 2265-2270.	2.0	10

#	Article	IF	Citations
37	Intestinal Transplant-Associated Thrombotic Microangiopathy: Histopathological Review. a Single Center Experience. Blood, 2018, 132, 3385-3385.	0.6	0
38	Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML. Bone Marrow Transplantation, 2017, 52, 1138-1143.	1.3	20
39	Results of a prospective phase II trial with ofatumumab as part of reduced intensity conditioning regimen in high-risk non-Hodgkin B lymphoma patients: A GELTAMO trial. Hematological Oncology, 2017, 35, 346-347.	0.8	0
40	Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. Bone Marrow Transplantation, 2017, 52, 438-444.	1.3	7
41	Biomarkers in Ocular Chronic Graft Versus Host Disease: Tear Cytokine- and Chemokine-Based Predictive Model. , 2016, 57, 746.		81
42	Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial. Clinical Cancer Research, 2016, 22, 5673-5681.	3.2	39
43	Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 1127-1136.	5.1	128
44	Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. Bone Marrow Transplantation, 2016, 51, 1307-1312.	1.3	31
45	Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Blood, 2016, 127, 1151-1162.	0.6	68
46	The Role of Hypomethylating Agents (Hma) in Early Myeloid Relapses After Allogenic Hematopoietic Stem Cell Transplant (HSCT). Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S84-S85.	0.2	0
47	Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. Biology of Blood and Marrow Transplantation, 2016, 22, 1808-1815.	2.0	29
48	GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study. Bone Marrow Transplantation, 2016, 51, 1524-1526.	1.3	6
49	Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center. Thrombosis Research, 2016, 142, 52-56.	0.8	12
50	Potential protective effect of Helicobacter pylori on the development of gastrointestinal GvHD. Bone Marrow Transplantation, 2016, 51, 819-824.	1.3	0
51	Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis. Blood, 2016, 128, 3308-3308.	0.6	2
52	Response to Proteosome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study. Blood, 2016, 128, 3436-3436.	0.6	1
53	Myeloablative Conditioning Haploidentical Stem Cell Transplantation (MAC-HAPLO) with Post-Transplant Cyclophosphamide (PTCy) As GvHD Prophylaxis in High Risk Leukemias/Myelosdysplastic Syndromes (MDS): Geth Experience. Blood, 2016, 128, 4690-4690.	0.6	2
54	Treatment of Patients with Steroid Refractory Acute Graft Vs Host Disease (SR-GvHD): A Matched Paired Analysis of Anti-CD26 (Begelomab) Compared to Other Treatment. Blood, 2016, 128, 671-671.	0.6	4

#	Article	IF	Citations
55	Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse. Oncotarget, 2016, 7, 80664-80679.	0.8	11
56	Acute graftâ€versusâ€host disease and bronchiolitis obliterans after autologous stem cell transplantation in a patient with multiple myeloma. Clinical Case Reports (discontinued), 2015, 3, 370-375.	0.2	4
57	The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 2015, 100, 683-689.	1.7	36
58	Gene Expressionâ€"Based Predictive Models of Graft Versus Host Diseaseâ€"Associated Dry Eye. , 2015, 56, 4570.		42
59	The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. Haematologica, 2015, 100, e53-e55.	1.7	41
60	In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?. Bone Marrow Transplantation, 2015, 50, 1411-1415.	1.3	16
61	Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome. Leukemia Research, 2015, 39, 828-834.	0.4	41
62	In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia, 2015, 29, 705-714.	3.3	72
63	GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT. Bone Marrow Transplantation, 2015, 50, 121-126.	1.3	8
64	Comparison of upfront tandem autologousâ€"allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma. Bone Marrow Transplantation, 2015, 50, 802-807.	1.3	13
65	Incidence and risk factors for lifeâ€threatening bleeding after allogeneic stem cell transplant. British Journal of Haematology, 2015, 169, 719-725.	1.2	37
66	An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation. Blood, 2015, 126, 3142-3142.	0.6	0
67	Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients. Blood, 2015, 126, 2955-2955.	0.6	0
68	Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2014, 49, 389-396.	1.3	92
69	Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica, 2014, 99, 1365-1372.	1.7	65
70	Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia, 2014, 28, 384-390.	3.3	252
71	Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia Research, 2014, 38, 551-556.	0.4	11
72	Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. Bone Marrow Transplantation, 2014, 49, 684-690.	1.3	46

#	Article	IF	Citations
73	Sequential Third-Party Mesenchymal Stromal Cell Therapy forÂRefractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 1580-1585.	2.0	99
74	Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. Bone Marrow Transplantation, 2014, 49, 1170-1175.	1.3	33
75	Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 66-72.	2.0	41
76	Long Term Follow-up on the Tretament of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival. Blood, 2014, 124, 3465-3465.	0.6	6
77	Strategies for Graft Versus Host Disease Prophylaxis after Reduced-Intensity Conditioning Transplantation: Combination of Sirolimus Plus Tacrolimus Allows to Obtain the Best Outcome. Blood, 2014, 124, 1165-1165.	0.6	0
78	Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine, 2013, 369, 438-447.	13.9	449
79	To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors. European Journal of Haematology, 2013, 91, 448-455.	1.1	28
80	Impact of Hyperferritinemia on the Outcome of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies. Biology of Blood and Marrow Transplantation, 2013, 19, 597-601.	2.0	6
81	Chronic graftâ€versusâ€host disease of the kidney in patients with allogenic hematopoietic stem cell transplant. European Journal of Haematology, 2013, 91, 129-134.	1.1	42
82	Phase <scp>II</scp> clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (<scp>RIC</scp>) and postâ€allogeneic transplantation for highâ€risk myeloma patients. British Journal of Haematology, 2013, 162, 474-482.	1.2	36
83	Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. Haematologica, 2013, 98, 437-443.	1.7	69
84	The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate. Haematologica, 2013, 98, 526-532.	1.7	30
85	The Presence Of 1 / 8 HLA Mismatch Do Not Hamper Survival After Allogeneic Stem Cell Transplantation Using Immunoprophylaxis With Sirolimus-Tacrolimus. Blood, 2013, 122, 4529-4529.	0.6	0
86	Identification Of Patients At High Risk Of Chronic Graft-Versus-Host Disease: Gvhd Prophylaxis. Blood, 2013, 122, 4611-4611.	0.6	0
87	Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 2012, 97, 310-317.	1.7	194
88	Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning. Bone Marrow Transplantation, 2012, 47, 1343-1349.	1.3	13
89	Genomic analysis of high-risk smoldering multiple myeloma. Haematologica, 2012, 97, 1439-1443.	1.7	43
90	SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia, 2012, 26, 2521-2529.	3.3	100

#	Article	IF	Citations
91	Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?. Haematologica, 2012, 97, 1608-1611.	1.7	17
92	Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia, 2012, 26, 1862-1869.	3.3	73
93	Endoscopic evaluation and histological findings in graft-versus-host disease. Revista Espanola De Enfermedades Digestivas, 2012, 104, 310-314.	0.1	12
94	Incidence and clinical characteristics of myeloproliferative neoplasms displaying a <scp>PDGFRB</scp> rearrangement. European Journal of Haematology, 2012, 89, 37-41.	1.1	42
95	Helicobacter pylori Infection and Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2011, 17, 765-769.	2.0	8
96	Pretransplantation Liver Function Impacts on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Study of 455 Patients. Biology of Blood and Marrow Transplantation, 2011, 17, 1653-1661.	2.0	17
97	Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia, 2011, 25, 697-706.	3.3	75
98	The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells. Clinical Cancer Research, 2011, 17, 1692-1700.	3.2	128
99	Cidofovir for BK Virusâ€“Associated Hemorrhagic Cystitis: A Retrospective Study. Clinical Infectious Diseases, 2009, 49, 233-240.	2.9	112
100	Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood, 2009, 113, 3781-3791.	0.6	78